X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs AJANTA PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH AJANTA PHARMA PANACEA BIOTECH/
AJANTA PHARMA
 
P/E (TTM) x 176.4 25.4 694.8% View Chart
P/BV x 3.9 10.5 37.4% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PANACEA BIOTECH   AJANTA PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
AJANTA PHARMA
Mar-16
PANACEA BIOTECH/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1491,720 8.6%   
Low Rs821,103 7.5%   
Sales per share (Unadj.) Rs84.1194.6 43.2%  
Earnings per share (Unadj.) Rs-18.345.2 -40.5%  
Cash flow per share (Unadj.) Rs-6.750.3 -13.3%  
Dividends per share (Unadj.) Rs08.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs83.7132.0 63.4%  
Shares outstanding (eoy) m61.2588.77 69.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.47.3 18.9%   
Avg P/E ratio x-6.331.2 -20.2%  
P/CF ratio (eoy) x-17.228.1 -61.4%  
Price / Book Value ratio x1.410.7 12.9%  
Dividend payout %017.7 0.0%   
Avg Mkt Cap Rs m7,074125,299 5.6%   
No. of employees `0002.8NA-   
Total wages/salary Rs m1,4492,570 56.4%   
Avg. sales/employee Rs Th1,874.1NM-  
Avg. wages/employee Rs Th527.0NM-  
Avg. net profit/employee Rs Th-407.7NM-  
INCOME DATA
Net Sales Rs m5,15417,275 29.8%  
Other income Rs m100166 60.0%   
Total revenues Rs m5,25417,442 30.1%   
Gross profit Rs m-7665,807 -13.2%  
Depreciation Rs m711451 157.8%   
Interest Rs m1,50349 3,073.6%   
Profit before tax Rs m-2,8815,474 -52.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m171,460 1.2%   
Profit after tax Rs m-1,1214,014 -27.9%  
Gross profit margin %-14.933.6 -44.2%  
Effective tax rate %-0.626.7 -2.2%   
Net profit margin %-21.823.2 -93.6%  
BALANCE SHEET DATA
Current assets Rs m3,8107,639 49.9%   
Current liabilities Rs m8,3652,715 308.1%   
Net working cap to sales %-88.428.5 -310.1%  
Current ratio x0.52.8 16.2%  
Inventory Days Days15643 360.2%  
Debtors Days Days6779 85.5%  
Net fixed assets Rs m14,4806,914 209.4%   
Share capital Rs m61177 34.7%   
"Free" reserves Rs m90311,442 7.9%   
Net worth Rs m5,12711,721 43.7%   
Long term debt Rs m5,832149 3,921.8%   
Total assets Rs m19,43314,814 131.2%  
Interest coverage x-0.9112.9 -0.8%   
Debt to equity ratio x1.10 8,965.1%  
Sales to assets ratio x0.31.2 22.7%   
Return on assets %2.027.4 7.2%  
Return on equity %-21.934.2 -63.9%  
Return on capital %3.646.5 7.8%  
Exports to sales %24.555.1 44.5%   
Imports to sales %10.26.0 169.5%   
Exports (fob) Rs m1,2649,527 13.3%   
Imports (cif) Rs m5251,038 50.6%   
Fx inflow Rs m1,53910,422 14.8%   
Fx outflow Rs m9421,678 56.1%   
Net fx Rs m5978,744 6.8%   
CASH FLOW
From Operations Rs m5993,264 18.4%  
From Investments Rs m-438-2,093 20.9%  
From Financial Activity Rs m-303-1,186 25.5%  
Net Cashflow Rs m-141-15 954.7%  

Share Holding

Indian Promoters % 74.5 73.8 100.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 1.6 38.7%  
FIIs % 1.3 7.6 17.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.0 138.8%  
Shareholders   10,259 20,968 48.9%  
Pledged promoter(s) holding % 35.1 4.4 798.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  UNICHEM LAB  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 16, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS